Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chattem Inc.

Division of Sanofi
www.chattem.com

Latest From Chattem Inc.

Sanofi's Consumer Health Q2 Results Ride Emerging Markets Boost

French pharma's worldwide OTC drug and other consumer health product sales grow 4.1% to $1.3bn led by more than 10% growth in its emerging markets, but US sales fell nearly 6% partly due to market-share incursion by private label OTCs.

Sales & Earnings Consumer

Supplements For Disease-Related Nutrition Shaping Consumer Health Landscape

Sales of dietary supplements promoted for nutritional needs of diabetics are exploding as consumers seek non-drug products to deal with symptoms of the disease, says a consumer health analyst in a recent presentation. Consumer health products positioned to prevent disease are growing at a much faster rate globally than those formulas that treat ailments.

International United States

Firms Spread Diaper Rash, Skin Care Brands, Move Lice Kit License In Recent Deals

Mission Pharmacal divested to MainPointe Pharmaceuticals topical analgesic brand Thera-Gesic and the Dr. Smith’s line of infant and adult skin protectant ointments and sprays. Randob Labs agreed to purchase the Balmex brand of baby and adult skin protectants from Moberg Pharma for $4.25m.
Commercial US States

Xyzal Claim To Match Zyrtec Efficacy At Half Dosage Dissolves In NAD Review

Claims that Sanofi's Xyzal 24 HR OTC product contains the same effectiveness as competitor Zyrtec but with half the medication fail a US

National Advertising Division review. NAD also recommended modifying claims suggesting Xyzal's pharmacological design confers a clinically meaningful benefit over Zyrtec.

Consumer Advertising, Marketing & Sales
See All

Company Information

  • Industry
  • Pharmaceuticals
    • OTC, Consumer
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Sanofi
  • Senior Management
  • Contact Info
  • Chattem Inc.
    Phone: (615) 821-4571
    1715 West 38th St.
    P.O. Box 2219 Chattanooga, TN 37409
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register